198 related articles for article (PubMed ID: 25668003)
1. Tailoring heated intraperitoneal mitomycin C for peritoneal metastases originating from colorectal carcinoma: a translational approach to improve survival.
Kwakman R; de Cuba EM; de Winter JP; de Hingh IH; Delis-van Diemen PM; Tijssen M; Rooimans MA; Krijgsman O; Carvalho B; Peters GJ; Bonjer HJ; Meijer GA; Te Velde EA
Br J Cancer; 2015 Mar; 112(5):851-6. PubMed ID: 25668003
[TBL] [Abstract][Full Text] [Related]
2. Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy.
Ubink I; Bolhaqueiro ACF; Elias SG; Raats DAE; Constantinides A; Peters NA; Wassenaar ECE; de Hingh IHJT; Rovers KP; van Grevenstein WMU; Laclé MM; Kops GJPL; Borel Rinkes IHM; Kranenburg O
Br J Surg; 2019 Sep; 106(10):1404-1414. PubMed ID: 31197820
[TBL] [Abstract][Full Text] [Related]
3. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery.
Prada-Villaverde A; Esquivel J; Lowy AM; Markman M; Chua T; Pelz J; Baratti D; Baumgartner JM; Berri R; Bretcha-Boix P; Deraco M; Flores-Ayala G; Glehen O; Gomez-Portilla A; González-Moreno S; Goodman M; Halkia E; Kusamura S; Moller M; Passot G; Pocard M; Salti G; Sardi A; Senthil M; Spiliotis J; Torres-Melero J; Turaga K; Trout R
J Surg Oncol; 2014 Dec; 110(7):779-85. PubMed ID: 25088304
[TBL] [Abstract][Full Text] [Related]
4. Identification of pharmacogenetic biomarkers for efficacy of cytoreductive surgery plus hyperthermic intraperitoneal mitomycin C in patients with colorectal peritoneal metastases.
Hulshof EC; Lurvink RJ; Caserta N; de Hingh IHJT; van Wezel T; Böhringer S; Swen JJ; Gelderblom H; Guchelaar HJ; Deenen MJ
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1925-1931. PubMed ID: 32354538
[TBL] [Abstract][Full Text] [Related]
5. A set of molecular markers predicts chemosensitivity to Mitomycin-C following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis.
Shannon NB; Tan JW; Tan HL; Wang W; Chen Y; Lim HJ; Tan QX; Hendrikson J; Ng WH; Loo LY; Skanthakumar T; Wasudevan SD; Kon OL; Lim TKH; Tan GHC; Chia CS; Soo KC; Ong CJ; Teo MCC
Sci Rep; 2019 Jul; 9(1):10572. PubMed ID: 31332257
[TBL] [Abstract][Full Text] [Related]
6. The Temperature-Dependent Effectiveness of Platinum-Based Drugs Mitomycin-C and 5-FU during Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer Cell Lines.
Helderman RFCPA; Löke DR; Verhoeff J; Rodermond HM; van Bochove GGW; Boon M; van Kesteren S; Garcia Vallejo JJ; Kok HP; Tanis PJ; Franken NAP; Crezee J; Oei AL
Cells; 2020 Jul; 9(8):. PubMed ID: 32722384
[TBL] [Abstract][Full Text] [Related]
7. Mitomycin C Pharmacokinetics as Predictor of Severe Neutropenia in Hyperthermic Intraperitoneal Therapy.
Kemmel V; Mercoli HA; Meyer N; Brumaru D; Romain B; Lessinger JM; Brigand C
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S873-9. PubMed ID: 26100819
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis.
Leung V; Huo YR; Liauw W; Morris DL
Eur J Surg Oncol; 2017 Jan; 43(1):144-149. PubMed ID: 27780675
[TBL] [Abstract][Full Text] [Related]
9. Colorectal peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: the experience of a tertiary Asian center.
Teo MC; Ching Tan GH; Lim C; Chia CS; Tham CK; Soo KC
Asian J Surg; 2015 Apr; 38(2):65-73. PubMed ID: 25059814
[TBL] [Abstract][Full Text] [Related]
10. The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study.
Hompes D; D'Hoore A; Wolthuis A; Fieuws S; Mirck B; Bruin S; Verwaal V
J Surg Oncol; 2014 May; 109(6):527-32. PubMed ID: 24375059
[TBL] [Abstract][Full Text] [Related]
11. Current status of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
Weber T; Roitman M; Link KH
Clin Colorectal Cancer; 2012 Sep; 11(3):167-76. PubMed ID: 22397952
[TBL] [Abstract][Full Text] [Related]
12. Hyperthermic intraperitoneal chemotherapy using a combination of mitomycin C,5-fluorouracil, and oxaliplatin in patients at high risk of colorectal peritoneal metastasis: A Phase I clinical study.
Shimizu T; Sonoda H; Murata S; Takebayashi K; Ohta H; Miyake T; Mekata E; Shiomi H; Naka S; Tani T
Eur J Surg Oncol; 2014 May; 40(5):521-528. PubMed ID: 24388411
[TBL] [Abstract][Full Text] [Related]
13. Angiogenesis-Related Markers and Prognosis After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Metastatic Colorectal Cancer.
de Cuba EM; de Hingh IH; Sluiter NR; Kwakman R; Coupé VM; Beliën JA; Verwaal VJ; Meijerink WJ; Delis-van Diemen PM; Bonjer HJ; Meijer GA; Te Velde EA
Ann Surg Oncol; 2016 May; 23(5):1601-8. PubMed ID: 26727921
[TBL] [Abstract][Full Text] [Related]
14. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis.
Lam JY; McConnell YJ; Rivard JD; Temple WJ; Mack LA
Am J Surg; 2015 Sep; 210(3):424-30. PubMed ID: 26051744
[TBL] [Abstract][Full Text] [Related]
15. Histologic and Immunohistochemical Alterations Associated with Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy.
Wagner P; Boone B; Ramalingam L; Jones H; Zureikat A; Holtzman M; Ahrendt S; Pingpank J; Zeh H; Choudry H; Bartlett D
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S588-95. PubMed ID: 25948159
[TBL] [Abstract][Full Text] [Related]
16. [Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal and appendiceal origin].
Berger Y; Zbar AP; Lebedyev A; Levi Y; Nevler A; Aderka D; Golan T; Purim O; Brenner B; Natur M; Gutman M
Harefuah; 2014 Jun; 153(6):315-9, 368. PubMed ID: 25095601
[TBL] [Abstract][Full Text] [Related]
17. Management of colorectal cancer patients at high risk of peritoneal metastases.
Shariff U; Seretis C; Youssef H
J BUON; 2015 May; 20 Suppl 1():S71-9. PubMed ID: 26051336
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.
Ceelen W; Van Nieuwenhove Y; Putte DV; Pattyn P
Ann Surg Oncol; 2014 Sep; 21(9):3023-8. PubMed ID: 24756812
[TBL] [Abstract][Full Text] [Related]
19. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery for peritoneal carcinomatosis in an experimental model.
Klaver YL; Hendriks T; Lomme RM; Rutten HJ; Bleichrodt RP; de Hingh IH
Br J Surg; 2010 Dec; 97(12):1874-80. PubMed ID: 20806291
[TBL] [Abstract][Full Text] [Related]
20. Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis.
Glockzin G; von Breitenbuch P; Schlitt HJ; Piso P
J Surg Oncol; 2013 May; 107(6):574-8. PubMed ID: 22833286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]